Jeffrey Bluestone

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Human antigen-specific regulatory T cells generated by T cell receptor gene transfer
    Todd M Brusko
    Diabetes Center, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 5:e11726. 2010
  2. pmc MicroRNA 10a marks regulatory T cells
    Lukas T Jeker
    Diabetes Center and the Department of Medicine, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 7:e36684. 2012
  3. pmc Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo
    Mahesh Yadav
    Diabetes Center, University of California, San Francisco, San Francisco, CA 94122, USA
    J Exp Med 209:1713-22, S1-19. 2012
  4. pmc DGCR8-mediated production of canonical microRNAs is critical for regulatory T cell function and stability
    Lukas T Jeker
    Diabetes Center and the Department of Medicine, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 8:e66282. 2013
  5. pmc CD28-inducible transcription factor DEC1 is required for efficient autoreactive CD4+ T cell response
    Marc Martínez-Llordella
    Diabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA
    J Exp Med 210:1603-19. 2013
  6. ncbi request reprint The future of cancer treatment: will it include immunotherapy?
    Jeffrey A Bluestone
    Diabetes Center, University of California San Francisco, 513 Parnassus Ave, San Francisco, CA 94143, USA
    Cancer Cell 22:7-8. 2012
  7. doi request reprint The Immune Tolerance Network at 10 years: tolerance research at the bedside
    Jeffrey A Bluestone
    Diabetes Center and Department of Medicine, University of California, San Francisco, San Francisco, California 94143, USA
    Nat Rev Immunol 10:797-803. 2010

Research Grants

  1. TOLERANCE OF ISLET CELL GRAFT
    Jeffrey Bluestone; Fiscal Year: 2001
  2. Spontaneous Autoimmune Model of Peripheral Neuropathy
    Jeffrey A Bluestone; Fiscal Year: 2010
  3. Spontaneous Autoimmune Model of Peripheral Neuropathy
    Jeffrey Bluestone; Fiscal Year: 2009
  4. Spontaneous Autoimmune Model of Peripheral Neuropathy
    Jeffrey Bluestone; Fiscal Year: 2007
  5. Spontaneous Autoimmune Model of Peripheral Neuropathy
    Jeffrey Bluestone; Fiscal Year: 2006
  6. Spontaneous Autoimmune Model of Peripheral Neuropathy
    Jeffrey Bluestone; Fiscal Year: 2005
  7. Spontaneous Autoimmune Model of Peripheral Neuropathy
    Jeffrey Bluestone; Fiscal Year: 2004
  8. Spontaneous Autoimmune Model of Peripheral Neuropathy
    Jeffrey Bluestone; Fiscal Year: 2003
  9. TOLERANCE OF ISLET CELL GRAFT
    Jeffrey Bluestone; Fiscal Year: 2000
  10. Spontaneous Autoimmune Model of Peripheral Neuropathy
    Jeffrey Bluestone; Fiscal Year: 2002

Collaborators

  • Gerald T Nepom
  • Mahesh Yadav
  • Lukas T Jeker
  • Marc Martínez-Llordella
  • Xuyu Zhou
  • Todd M Brusko
  • Dennis D Taub
  • Ann Marini
  • Robert H Lipsky
  • Jun Chen
  • Mark P Mattson
  • Mohamed Mughal
  • Robert Blelloch
  • Jonathan H Esensten
  • Samantha L Bailey-Bucktrout
  • Dimitri de Kouchkovsky
  • Anders H Lund
  • Kseniya Gershberg
  • Gustavo Stadthagen
  • Malika M Morar
  • Antoni Ribas
  • Amy L Putnam
  • Lung Ji Chang
  • Mark A Atkinson
  • Richard C Koya
  • Shuhong Han
  • Michael R Lee
  • Shirley Zhu
  • Stephanie A McClymont
  • Michael I Nishimura

Detail Information

Publications8

  1. pmc Human antigen-specific regulatory T cells generated by T cell receptor gene transfer
    Todd M Brusko
    Diabetes Center, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 5:e11726. 2010
    ..Moreover, FOXP3+ Tregs fall largely within the CD4+ T cell subset and are thus routinely MHC class II-specific, whereas class I-specific Tregs may function optimally in vivo by facilitating direct tissue recognition...
  2. pmc MicroRNA 10a marks regulatory T cells
    Lukas T Jeker
    Diabetes Center and the Department of Medicine, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 7:e36684. 2012
    ..Thus, miR-10a is selectively expressed in Treg but inhibition by antagomiRs or genetic ablation resulted in discordant effects on FoxP3...
  3. pmc Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo
    Mahesh Yadav
    Diabetes Center, University of California, San Francisco, San Francisco, CA 94122, USA
    J Exp Med 209:1713-22, S1-19. 2012
    ..Collectively, our data show that Nrp-1 provides an excellent marker to distinguish distinct T reg subsets and will be useful in studying the role of nT reg versus iT reg cells in different disease settings...
  4. pmc DGCR8-mediated production of canonical microRNAs is critical for regulatory T cell function and stability
    Lukas T Jeker
    Diabetes Center and the Department of Medicine, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 8:e66282. 2013
    ..We conclude that canonical miRNAs are essential to maintain stable FoxP3 expression and Treg function. Thus, signals interfering with miRNA homeostasis might contribute to autoimmune diseases...
  5. pmc CD28-inducible transcription factor DEC1 is required for efficient autoreactive CD4+ T cell response
    Marc Martínez-Llordella
    Diabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA
    J Exp Med 210:1603-19. 2013
    ..Thus, we identify DEC1 as a critical transcriptional mediator in the activation of naive CD4(+) T cells that is required for the development of a T cell-mediated autoimmune disease. ..
  6. ncbi request reprint The future of cancer treatment: will it include immunotherapy?
    Jeffrey A Bluestone
    Diabetes Center, University of California San Francisco, 513 Parnassus Ave, San Francisco, CA 94143, USA
    Cancer Cell 22:7-8. 2012
    ..In one of these trials, efficacy was linked to the expression of the PD-L1 biomarker on tumor cells...
  7. doi request reprint The Immune Tolerance Network at 10 years: tolerance research at the bedside
    Jeffrey A Bluestone
    Diabetes Center and Department of Medicine, University of California, San Francisco, San Francisco, California 94143, USA
    Nat Rev Immunol 10:797-803. 2010
    ..ITN investigators have published more than 80 original research papers based on this work. This Timeline article summarizes the progress and challenges of clinical research in the ITN...

Research Grants12

  1. TOLERANCE OF ISLET CELL GRAFT
    Jeffrey Bluestone; Fiscal Year: 2001
    ..The outcome of these studies will have important implications for islet cell transplantation for the treatment of IDDM. ..
  2. Spontaneous Autoimmune Model of Peripheral Neuropathy
    Jeffrey A Bluestone; Fiscal Year: 2010
    ..Moreover these common and distinct pathways are critical for understanding of the immunopathology of these different autoimmune diseases and development of novel therapies. ..
  3. Spontaneous Autoimmune Model of Peripheral Neuropathy
    Jeffrey Bluestone; Fiscal Year: 2009
    ..Moreover these common and distinct pathways are critical for understanding of the immunopathology of these different autoimmune diseases and development of novel therapies. ..
  4. Spontaneous Autoimmune Model of Peripheral Neuropathy
    Jeffrey Bluestone; Fiscal Year: 2007
    ..Moreover these common and distinct pathways are critical for understanding of the immunopathology of these different autoimmune diseases and development of novel therapies. ..
  5. Spontaneous Autoimmune Model of Peripheral Neuropathy
    Jeffrey Bluestone; Fiscal Year: 2006
    ....
  6. Spontaneous Autoimmune Model of Peripheral Neuropathy
    Jeffrey Bluestone; Fiscal Year: 2005
    ....
  7. Spontaneous Autoimmune Model of Peripheral Neuropathy
    Jeffrey Bluestone; Fiscal Year: 2004
    ....
  8. Spontaneous Autoimmune Model of Peripheral Neuropathy
    Jeffrey Bluestone; Fiscal Year: 2003
    ....
  9. TOLERANCE OF ISLET CELL GRAFT
    Jeffrey Bluestone; Fiscal Year: 2000
    ..The outcome of these studies will have important implications for islet cell transplantation for the treatment of IDDM. ..
  10. Spontaneous Autoimmune Model of Peripheral Neuropathy
    Jeffrey Bluestone; Fiscal Year: 2002
    ....
  11. Spontaneous Autoimmune Model of Peripheral Neuropathy
    Jeffrey A Bluestone; Fiscal Year: 2010
    ..Moreover these common and distinct pathways are critical for understanding of the immunopathology of these different autoimmune diseases and development of novel therapies. ..